Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System
Findings from the first two years of a five-year, real-world study, which was published in the Journal of Clinical Oncology (JCO)reveal that Comprehensive Genomic Profiling (CGP), when done early in a cancer patient’s diagnosis, leads to better personalized treatment and patient outcomes.
This new research by Providence, Illumina, and Microsoft showed that using CGP testing finds more useful genetic changes than an older 50-gene test. Patients tested with CGP were more likely to get targeted treatments and lived longer when tested at diagnosis. However, not all patients get CGP testing, so there are still some gaps in who benefits from this approach.
